Trial · NCT03218917
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period | Brensocatib 10 mg | NA | 90% Confidence Interval NA to NA | days | |
| Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period | Brensocatib 25 mg | NA | 90% Confidence Interval NA to NA | days | |
| Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period | Placebo | 189.0 | 90% Confidence Interval 141.0 to NA | days | |
| Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period | Brensocatib 10 mg | 3.8 | Standard Error 0.78 | score on a scale | |
| Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period | Brensocatib 25 mg | 5.9 | Standard Error 0.76 | score on a scale | |
| Change From Baseline in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score Over 24 Week Treatment Period | Placebo | 5.7 | Standard Error 0.77 | score on a scale | |
| Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period | Brensocatib 10 mg | -0.3 | Standard Error 0.88 | percent predicted FEV1 | |
| Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period | Brensocatib 25 mg | -0.3 | Standard Error 0.85 | percent predicted FEV1 | |
| Change From Screening in Post-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Over 24-Week Treatment Period | Placebo | -1.8 | Standard Error 0.87 | percent predicted FEV1 | |
| Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum | Brensocatib 10 mg | -2.928 | Standard Error 0.351 | microgram/ milliliter (µg/mL) | |
| Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum | Brensocatib 25 mg | -4.117 | Standard Error 0.322 | microgram/ milliliter (µg/mL) | |
| Change From Baseline in Concentration of Active Neutrophil Elastase (NE) in Sputum | Placebo | -1.409 | Standard Error 0.313 | microgram/ milliliter (µg/mL) | |
| Number of Participants Who Experienced a Pulmonary Exacerbation | Brensocatib 10 mg | 26 | Participants | ||
| Number of Participants Who Experienced a Pulmonary Exacerbation | Brensocatib 25 mg | 29 | Participants | ||
| Number of Participants Who Experienced a Pulmonary Exacerbation | Placebo | 42 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03218917/results